Comparative Pharmacology
Head-to-head clinical analysis: SPIRIVA versus SPIRIVA RESPIMAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SPIRIVA versus SPIRIVA RESPIMAT.
SPIRIVA vs SPIRIVA RESPIMAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tiotropium is a long-acting muscarinic antagonist (LAMA) that blocks M3 receptors in the airways, inhibiting acetylcholine-induced bronchoconstriction and mucus secretion.
Long-acting muscarinic antagonist (LAMA) that inhibits acetylcholine at M3 receptors in bronchial smooth muscle, leading to bronchodilation.
18 mcg inhalation via HandiHaler once daily, or 2.5 mcg (2 puffs) via Respimat inhaler once daily.
2 actuations (2.5 mcg tiotropium/actuation) once daily by oral inhalation.
None Documented
None Documented
Terminal elimination half-life is 27–46 hours (mean ~30 hours) after inhalation. The long half-life supports once-daily dosing due to sustained bronchodilation.
Terminal elimination half-life of 27 hours after inhalation (range 13-50 hours), supporting once-daily dosing due to prolonged receptor binding.
Renal excretion accounts for approximately 60% (mainly as unchanged drug) following intravenous administration; biliary/fecal excretion accounts for about 30% (as non-absorbed drug after oral inhalation). Less than 20% is metabolized via ester hydrolysis (nonspecific esterases) to inactive metabolites.
Renal excretion (60-70% unchanged) and biliary/fecal excretion (30-40%) after IV administration; after inhalation, most of the swallowed dose is eliminated fecally.
Category C
Category C
Anticholinergic Bronchodilator
Anticholinergic Bronchodilator